Anti-TIF1-γ-associated dermatomyositis associated with recurrent metastatic triple-negative breast cancer: Dramatic clinical response to sacituzumab govitecan

被引：0
|
作者：
Wang, Wei-Yao [1 ,2 ]
Lee, Chin-Yu [1 ,2 ]
Hu, Stephen Chu-Sung [1 ,2 ,3 ]
机构：
[1] Kaohsiung Med Univ Hosp, Dept Dermatol, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Dept Dermatol, Kaohsiung, Taiwan
[3] Kaohsiung Municipal Siaogang Hosp, Dept Dermatol, Kaohsiung, Taiwan
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2024年 / 22卷 / 07期
关键词：
Anti-transcriptional intermediary factor 1 gamma antibody; breast cancer; dermatomyositis; paraneoplastic syndrome; sacituzumab govitecan; AUTOANTIBODIES;
D O I：
10.1111/ddg.15399
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1008 / 1011
页数：4
相关论文
共 50 条
  • [41] Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Chen, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S650 - S650
  • [42] Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies
    Muro, Yoshinao
    Ishikawa, Asuka
    Sugiura, Kazumitsu
    Akiyama, Masashi
    RHEUMATOLOGY, 2012, 51 (08) : 1508 - 1513
  • [43] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie
    SiNi Li
    YaMin Li
    JianHe Li
    BMC Health Services Research, 23
  • [44] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931
  • [45] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Xie, Jiao
    Li, SiNi
    Li, YaMin
    Li, JianHe
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [46] Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
    Cher, Boon Piang
    Goh, Sharon
    Aziz, Mohamed Ismail Abdul
    Wong, Grace
    Hui, Raymond Ng Chee
    Ong, Benjamin Shao-Kiat
    Ng, Kwong-Hoe
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (02) : 217 - 225
  • [47] Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
    Khan, Saif
    Jandrajupalli, Suresh Babu
    Bushara, Nashwa Zaki Ali
    Raja, Rama Devi Patel
    Mirza, Shadab
    Sharma, Kuldeep
    Verma, Rajan
    Kumar, Ashish
    Lohani, Mohtashim
    CELLS, 2024, 13 (24)
  • [48] Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.
    Khalid, Farhan
    Kashyap, Richi
    Singh, Vinit
    Tayyeb, Muhammad
    Jaan, Ali
    Mohan, Gaurav
    Meghal, Trishala
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
  • [50] Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report
    Ondřej Kubeček
    Tomáš Soukup
    Adam Paulík
    Jindřich Kopecký
    BMC Cancer, 16
12345